Inspire Medical Systems, Inc.
INSP
NYSE·Healthcare·Medical - Devices·Mkt cap $1.8B
$63.08
▲ +1.51%
P/E
13.54
Mkt Cap
$1.8B
52-Wk Range
$38.91–$147.03
52-Week Range
$38.91 - $147.03
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary neurostimulation technology with strong clinical validation
- FDA approval and market leadership in hypoglossal nerve stimulation
- High patient compliance and satisfaction rates versus alternative therapies
- Expanding reimbursement coverage and growing physician network
Bear Case
2 risks
- Low volatility (beta 0.7).
- High premium - requires strong execution
Growth
Stable outlook
Increasing diagnosis and treatment rates in OSA patient population
Value
High premium - requires strong execution
Momentum
Hot
+50.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying INSP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 3, 2026
Reported EPS of $0.14 vs -$0.24 consensus (+159.3% surprise). Revenue of $200.6M vs $194.7M expected (+3.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+159.3%
Revenue trend · last 8Q
—
—
+23%
+11%
+10%
+12%
+2%
-8%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$203.2M
$239.7M
$201.3M
$217.1M
$224.5M
$269.1M
$204.6M
$200.6M
Margins · last 8Q
Gross
85.5%
Operating
-0.3%
Profit
0.2%
Wall Street consensus
11 analysts · 45% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
45%
Hold
45%
Sell
9%
Median Price Target
—
Latest: Oppenheimer · Aug 4, 2026
vs Industry
How INSP stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related